US Patent

US9795604 — Methods of treating and preventing graft versus host disease

Method of Use · Assigned to Pharmacyclics LLC · Expires 2034-10-24 · 8y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods for treating and preventing graft versus host disease using ACK inhibitors, such as administering ibrutinib.

USPTO Abstract

Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.

Drugs covered by this patent

Imbruvica (ibrutinib) · AbbVie

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2969`	—	Imbruvica
`U-3422`	—	Imbruvica
`U-3422`	—	Imbruvica
`U-2150`	—	Imbruvica
`U-3422`	—	Imbruvica
`U-3422`	—	Imbruvica
`U-3422`	—	Imbruvica

Patent Metadata

Patent number: US9795604
Jurisdiction: US
Classification: Method of Use
Expires: 2034-10-24
Drug substance claim: No
Drug product claim: No
Assignee: Pharmacyclics LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.